BioMarin
BioMarin Veterans Launch Mendra Biotech with $82M for AI-Driven Rare Disease Drugs
Mendra; BioMarin; rare disease; biotech startup; $82M; Series A; AI drug development
BioMarin Announces $4.8 Billion Acquisition of Amicus Therapeutics for Rare Disease Portfolio Expansion
BioMarin; Amicus Therapeutics; acquisition; $4.8B; Galafold; Pombiliti; Opfolda; rare diseases
BioMarin Plans to Divest Hemophilia Gene Therapy Roctavian Amid Strategic Refocus
BioMarin; Roctavian; hemophilia A; gene therapy; divestment; out-licensing; portfolio strategy; third quarter 2025; revenue challenge
BioMarin Drops Preclinical PKU Drug Once Seen as Potential Palynziq Successor
BioMarin; PKU; Palynziq; BMN 390; drug development; R&D pipeline; immunogenicity
BioMarin Acquires Inozyme Pharma for $270M, Gaining Phase 3 Rare Disease Therapy
BioMarin; Inozyme Pharma; acquisition; rare disease; INZ-701; ENPP1 Deficiency; enzyme replacement therapy; Phase 3 clinical trial
BioMarin’s R&D Chief Warns of Innovation Slowdown Amid NIH Funding Cuts
BioMarin, NIH funding, biomedical innovation, genetic diseases, drug development, research partnerships
Emerging Competitors in Achondroplasia Treatment: BioMarin’s Dominance Faces New Challenges
Achondroplasia, BioMarin, Voxzogo, BridgeBio, infigratinib, TransCon CNP, RBM-007, skeletal disorders, dwarfism, genetic bone disorders.
BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases
BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions
Ascendis Challenges BioMarin’s Dominance with Promising Achondroplasia Drug Data
Achondroplasia, Ascendis Pharma, BioMarin, TransCon CNP, VOXZOGO, Dwarfism Treatment
BioMarin Undergoes Strategic Restructuring Amid Slow Roctavian Sales and Staff Layoffs
BioMarin, restructuring, Roctavian, staff layoffs, corporate strategy, hemophilia gene therapy